ClinicalTrials.gg
CompletedNCT03785340Updated Jul 18, 2022Results posted

Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)

A Phase 3 interventional study of Brimonidine Tartrate and Placebos in Dry Eye, sponsored by Ocugen. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-18.

Sponsored by Ocugen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.

Enrollment
84th of 473
252 · median 60
Started
2018
with 35 others
Phase 3
77 of 544
1 open now
Registered
281st of 544
by date

Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 84th largest by enrollment of the 473 interventional ones that give a count, is one of 36 that started in 2018, is one of 77 in phase 3, and was the 281st registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 544 studies in Dry Eye Syndromes with a site in United States, or all of them as a file.
02

Study summary

This study evaluates the use of Brimonidine tartrate nanoemulsion eye drop solution in the treatment of Dry Eye Disease (DED). Half of participants will receive Brimonidine and half will receive ophthalmic buffered saline (placebo).

Read the detailed description

Dry eye disease (DED) is a common ocular disorder involving the aberrant production and instability of tear film, which results in damage to the ocular surface and is correlated with symptoms of ocular discomfort.

This study will be a randomized, placebo-controlled, double-masked, multicenter phase 3 study in the United States conducted at approximately 25 centers. Upon meeting the eligibility criteria, enrolled subjects will be randomly assigned in a 1:1 (test:control) fashion to receive either Brimonidine Nanoemulsion Eye Drops 0.20% investigational product (test) or ophthalmic buffered saline (placebo).

03

Conditions studied

  • Dry Eye

Browse trials for

Keywords

  • Dry Eye Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 years or older.
  2. Sign and date form approved by the IRB
  3. History of Dry Eye Disease for ≥6 months
  4. Demonstrate the following 2 signs of DED in the same eye at Screening and Baseline (Day 1):

    1. Conjunctival staining at ≥3 (out of a possible score of 6 per eye), and
    2. Schirmer test (with anesthesia) at ≥1 to ≤7mm in 5 minutes
  5. Symptomatic evidence of DED by having a global symptom score (Overall SANDE) ≥40 mm at Screening and Baseline (Day 1) visit
  6. Intraocular pressure (IOP) ≥ 5 mmHg and ≤22 mmHg in each eye
  7. Women who satisfy one of the following:

8a. Are of (WOCP) who are not pregnant or lactating and who are either abstinent or sexually active on an acceptable method of for at least 4 weeks prior to Visit 1 and throughout the study (i.e., until Day 28), OR 8b. Are or have undergone a sterilization procedure

Exclusion criteria

Exclusion Criteria:

  1. Allergic to brimonidine or any similar products, or of brimonidine
  2. Use of contact lenses within 14 days prior to Screening visit or planned use during study
  3. Currently receiving brimonidine or other treatment for glaucoma or ocular hypertension or history of glaucoma surgery.
  4. Receiving or have received any experimental or drug or device within 30 days prior to Screening visit
  5. Intraocular pressure \<5 mmHg or >22 mmHg in either eye
  6. Active ocular infection or history of ocular herpetic keratitis
  7. History of neurotrophic keratitis or ocular neuropathic pain
  8. Any history of eyelid surgery or intraocular/ocular surgery within the past 3 months
  9. Punctal occlusion within 3 months prior to Screening visit or during study
  10. Corneal epithelial defect larger than 1 mm2 in either eye
  11. Have active drug/alcohol dependence or abuse history
  12. Are neonates, pregnant/lactating women, children, or others who may be considered vulnerable populations
  13. Received -containing eye drops within 14 days prior to Screening visit or planned use during study
  14. Any change in systemic corticosteroids/immunosuppressives, cyclosporine ophthalmic emulsion 0.05% (Restasis®), cyclosporine ophthalmic solution 0.09% (Cequa™), or lifitegrast ophthalmic solution 5% (Xiidra®) within 30 days prior to Screening visit or planned change during study
  15. In the opinion of Investigator or Study Coordinator, be unwilling or unable to comply with study protocol or unable to successfully instill eye drops
  16. Disease, condition, or disorder that in the judgement of Investigator could confound study assessments or limit compliance to study protocol
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
252 participants (actual)

Study arms

  • Experimental
    OCU-310

    Brimonidine Tartrate Nanoemulsion Eye Drops 0.20% given 2 times a day for 4 weeks

    Drug: Brimonidine Tartrate

  • Placebo comparator
    Placebos

    Ophthalmic buffered saline Eye Drops given 2 times a day for 4 weeks

    Drug: Placebos

Interventions

  • Brimonidine Tartrate Nanoemulsion Eye Drops 0.20% given 2 times a day for 4 weeks.

    Also known as: OCU-310

  • DrugPlacebos

    Ophthalmic buffered saline Eye Drops given 2 times a day for 4 weeks.

    Also known as: Ophthalmic buffered saline solution

06

What researchers measure

Primary outcomes

  1. Change From Baseline to 4 Weeks (Day 28) in Symptom Assessment in Dry Eye (SANDE) Questionnaire Score

    The SANDE questionnaire is a short Visual Analog Scale (VAS) assessment that quantifies both severity and frequency of current dry eye symptoms. The SANDE is comprised of two questions, and each question employs a 100-mm horizontal linear VAS. The measurement of symptom frequency ranges from "rarely" to "all of the time", and the symptom severity from "very mild" to "very severe". Data collected from the SANDE questionnaire was calculated by multiplying the frequency score by the severity score and obtaining the square root. The result is the Overall SANDE score which ranges from 0 to 100 with 100 being the maximal amount of dry eye symptoms and 0 being the minimal amount of dry eye symptoms.

    Time frame: Baseline, 4 weeks (Day 28)

  2. Change From Baseline to 4 Weeks (Day 28) in Lissamine Green Conjunctival Staining Scores

    Conjunctival staining with Lissamine Green dye (1%; LG) staining in each eye was conducted using the slit lamp. A single drop of 1% Lissamine Green dye was applied to the inferior conjunctival fornix of both eyes. The conjunctivae was examined with the slit lamp at ×10 magnification, using a neutral-density filter. The conjunctiva was graded for each eye from 0 to 3 based on the density of punctate staining in the nasal-bulbar and temporal-bulbar zones. Total scores ranged from 0 (no staining) to 6 (most severe staining) with a lower score representing a more desirable outcome.

    Time frame: Baseline, 4 Weeks (Day 28)

Secondary outcomes

  1. Change From Baseline to 2 Weeks (Day 14) in SANDE Score

    The SANDE questionnaire is a short Visual Analog Scale (VAS) assessment that quantifies both severity and frequency of current dry eye symptoms. The SANDE is comprised of two questions, and each question employs a 100-mm horizontal linear VAS. The measurement of symptom frequency ranges from "rarely" to "all of the time", and the symptom severity from "very mild" to "very severe". Data collected from the SANDE questionnaire was calculated by multiplying the frequency score by the severity score and obtaining the square root. The result is the Overall SANDE score which ranges from 0 to 100 with 100 being the maximal amount of dry eye symptoms and 0 being the minimal amount of dry eye symptoms.

    Time frame: Baseline, 2 weeks (Day 14)

  2. Change From Baseline to 2 Weeks (Day 14) in Lissamine Green Conjunctival Staining Scores

    Conjunctival staining with Lissamine Green dye (1%; LG) staining in each eye was conducted using the slit lamp. A single drop of 1% Lissamine Green dye was applied to the inferior conjunctival fornix of both eyes. The conjunctivae was examined with the slit lamp at ×10 magnification, using a neutral-density filter. The conjunctiva was graded for each eye from 0 to 3 based on the density of punctate staining in the nasal-bulbar and temporal-bulbar zones. Total scores ranged from 0 (no staining) to 6 (most severe staining) with a lower score representing a more desirable outcome.

    Time frame: Baseline, 2 Weeks (Day 14)

07

Results

Posted Jun 6, 2022

Participant flow

Participant flow — Overall Study
MilestoneOCU-310Placebo
Started126126
Received at least 1 study treatment126126
Completed123126
Not completed30
Withdrew: Lost to follow-up20
Withdrew: Adverse event10

Outcome measures

PrimaryChange From Baseline to 4 Weeks (Day 28) in Symptom Assessment in Dry Eye (SANDE) Questionnaire Score

The SANDE questionnaire is a short Visual Analog Scale (VAS) assessment that quantifies both severity and frequency of current dry eye symptoms. The SANDE is comprised of two questions, and each question employs a 100-mm horizontal linear VAS. The measurement of symptom frequency ranges from "rarely" to "all of the time", and the symptom severity from "very mild" to "very severe". Data collected from the SANDE questionnaire was calculated by multiplying the frequency score by the severity score and obtaining the square root. The result is the Overall SANDE score which ranges from 0 to 100 with 100 being the maximal amount of dry eye symptoms and 0 being the minimal amount of dry eye symptoms.

Time frame:
Baseline, 4 weeks (Day 28)
Reported as:
Mean · Score on a scale
Change From Baseline to 4 Weeks (Day 28) in Symptom Assessment in Dry Eye (SANDE) Questionnaire Score
Score on a scaleOCU-310Placebo
Baseline73.0 ± 13.672.7 ± 12.4
4 weeks (Day 28)56.6 ± 23.257.2 ± 19.8
Change from Baseline at 4 weeks (Day 28)-16.4 ± 20.9-15.5 ± 19.9
Statistical analysis
  • OCU-310 vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.739 · Least squares mean difference: -0.844 · 95% CI -5.823 to 4.134Change from baseline to 4 weeks (Day 28) in SANDE score; OCU-310 vs. Placebo
PrimaryChange From Baseline to 4 Weeks (Day 28) in Lissamine Green Conjunctival Staining Scores

Conjunctival staining with Lissamine Green dye (1%; LG) staining in each eye was conducted using the slit lamp. A single drop of 1% Lissamine Green dye was applied to the inferior conjunctival fornix of both eyes. The conjunctivae was examined with the slit lamp at ×10 magnification, using a neutral-density filter. The conjunctiva was graded for each eye from 0 to 3 based on the density of punctate staining in the nasal-bulbar and temporal-bulbar zones. Total scores ranged from 0 (no staining) to 6 (most severe staining) with a lower score representing a more desirable outcome.

Time frame:
Baseline, 4 Weeks (Day 28)
Reported as:
Mean · score on a scale
Change From Baseline to 4 Weeks (Day 28) in Lissamine Green Conjunctival Staining Scores
score on a scaleOCU-310Placebo
Baseline4.2 ± 1.14.1 ± 1.0
4 Weeks (Day 28)3.6 ± 1.63.2 ± 1.3
Change from Baseline at 4 Weeks (Day 28)-0.6 ± 1.4-0.9 ± 1.1
SecondaryChange From Baseline to 2 Weeks (Day 14) in SANDE Score

The SANDE questionnaire is a short Visual Analog Scale (VAS) assessment that quantifies both severity and frequency of current dry eye symptoms. The SANDE is comprised of two questions, and each question employs a 100-mm horizontal linear VAS. The measurement of symptom frequency ranges from "rarely" to "all of the time", and the symptom severity from "very mild" to "very severe". Data collected from the SANDE questionnaire was calculated by multiplying the frequency score by the severity score and obtaining the square root. The result is the Overall SANDE score which ranges from 0 to 100 with 100 being the maximal amount of dry eye symptoms and 0 being the minimal amount of dry eye symptoms.

Time frame:
Baseline, 2 weeks (Day 14)
Reported as:
Mean · score on a scale
Change From Baseline to 2 Weeks (Day 14) in SANDE Score
score on a scaleOCU-310Placebo
Baseline73.0 ± 13.672.7 ± 12.4
2 weeks (Day 14)61.3 ± 20.558.6 ± 17.5
Change from Baseline at 2 weeks (Day 14)-11.6 ± 18.3-14.1 ± 16.3
SecondaryChange From Baseline to 2 Weeks (Day 14) in Lissamine Green Conjunctival Staining Scores

Conjunctival staining with Lissamine Green dye (1%; LG) staining in each eye was conducted using the slit lamp. A single drop of 1% Lissamine Green dye was applied to the inferior conjunctival fornix of both eyes. The conjunctivae was examined with the slit lamp at ×10 magnification, using a neutral-density filter. The conjunctiva was graded for each eye from 0 to 3 based on the density of punctate staining in the nasal-bulbar and temporal-bulbar zones. Total scores ranged from 0 (no staining) to 6 (most severe staining) with a lower score representing a more desirable outcome.

Time frame:
Baseline, 2 Weeks (Day 14)
Reported as:
Mean · score on a scale
Change From Baseline to 2 Weeks (Day 14) in Lissamine Green Conjunctival Staining Scores
score on a scaleOCU-310Placebo
Baseline4.2 ± 1.14.1 ± 1.0
2 Weeks (Day 14)3.8 ± 1.43.4 ± 1.3
Change from Baseline at 2 Weeks (Day 14)-0.4 ± 1.2-0.7 ± 1.0

Adverse events

Collected over Adverse events were collected from the time of informed consent completion, throughout the study, and at early termination (Up to 28 Days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OCU-3100/126 (0%)0/126 (0%)0/126 (0%)
Placebo0/126 (0%)0/126 (0%)0/126 (0%)

Baseline characteristics

Randomized set: All randomized participants who previously signed the informed consent.

Age, Continuous
Age, Continuous(years)OCU-310PlaceboTotal
Mean61.7 (27 to 85)62.1 (24 to 85)62 (24 to 85)
Sex: Female, Male
Sex: Female, Male(Participants)OCU-310PlaceboTotal
Sex — Female106105211
Sex — Male202141
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OCU-310PlaceboTotal
Hispanic or Latino121123
Not Hispanic or Latino114115229
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OCU-310PlaceboTotal
American Indian or Alaska Native101
Asian437
Native Hawaiian or Other Pacific Islander000
Black or African American191130
White101111212
More than one race112
Unknown or Not Reported000
08

Study locations

16 sites
  • Aesthetic Eye Care Institute/David Wirta, MD and Associates
    Newport Beach, California 92663, United States
  • Martel Medical Eye Group
    Rancho Cordova, California 95670, United States
  • Rand Eye Institute
    Pompano Beach, Florida 33064, United States
  • Chicago Cornea Consultants
    Hoffman Estates, Illinois 60169, United States
  • Heart of America Eye Care, P. A.
    Mission, Kansas 66204, United States
  • Ophthalmology Associates
    Saint Louis, Missouri 63131, United States
  • Apex Eye- Kenwood
    Cincinnati, Ohio 45236, United States
  • Apex Eye-Montgomery
    Cincinnati, Ohio 45242, United States
  • Abrams Eye Center
    Cleveland, Ohio 44115, United States
  • Scott and Christie Eyecare Associates
    Cranberry Township, Pennsylvania 16066, United States
  • Total Eye Care
    Memphis, Tennessee 38119, United States
  • Toyos Clinic
    Nashville, Tennessee 37215, United States
  • Midtown Eye Physicans & Associates
    Houston, Texas 77004, United States
  • Advanced Laser Vision & Surgical Institute
    Houston, Texas 77034, United States
  • Revolution Research, Inc; Lake Travis Eye and Laser Center
    Lakeway, Texas 78734, United States
  • The Eye Institute of Utah
    Salt Lake City, Utah 84107, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Feb 2019, 2 months.

Results were first posted in Jun 2022, 3 years 3 months after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 2 months is below that.

Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2018
First posted
Dec 24, 2018
StartActual
Dec 3, 2018
Primary completionActual
Feb 25, 2019
CompletionActual
Feb 25, 2019
Results first posted
Jun 6, 2022
Last update
Jul 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03785340
Lead sponsor
Ocugen
Responsible party
Sponsor
First posted
Dec 24, 2018
Start date
Dec 3, 2018
Primary completion
Feb 25, 2019
Completion
Feb 25, 2019
Results posted
Jun 6, 2022
Last update
Jul 18, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion